Literature DB >> 25228503

Interplay between the immune system and adipose tissue in obesity.

Mark A Exley1, Laura Hand2, Donal O'Shea2, Lydia Lynch2.   

Abstract

Obesity is a major risk factor for metabolic disease, with white adipose tissue (WAT) inflammation emerging as a key underlying pathology. Alongside its major role in energy storage, WAT is an important endocrine organ, producing many bioactive molecules, termed adipokines, which not only serve as regulators of systemic metabolism, but also possess immunoregulatory properties. Furthermore, WAT contains a unique immune cell repertoire, including an accumulation of leukocytes that are rare in other locations. These include alternatively activated macrophages, invariant natural killer T cells, and regulatory T cells. Disruption of resident adipose leukocyte homeostasis contributes to obesity-associated inflammation and consequent metabolic disorder. Despite many recent advances in this new field of immuno-metabolism, fundamental questions of why and how inflammation arises as obesity develops are not yet fully understood. Exploring the distinct immune system of adipose tissue is fundamental to our understanding of the endocrine as well as immune systems. In this review, we discuss the roles of adipose tissue leukocytes in the transition to obesity and progression of inflammation and highlight potential anti-inflammatory therapies for combating obesity-related pathology.
© 2014 Society for Endocrinology.

Entities:  

Keywords:  CD1d; NKT cells; adipocytes; lipids

Mesh:

Year:  2014        PMID: 25228503     DOI: 10.1530/JOE-13-0516

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  75 in total

Review 1.  Considerations for dosing immunoglobulin in obese patients.

Authors:  J P Hodkinson
Journal:  Clin Exp Immunol       Date:  2017-04-17       Impact factor: 4.330

Review 2.  [Obesity and autoimmunity : Adipose tissue as an immune organ?]

Authors:  S Thrum
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

Review 3.  Endocrine disruptors and obesity.

Authors:  Jerrold J Heindel; Retha Newbold; Thaddeus T Schug
Journal:  Nat Rev Endocrinol       Date:  2015-09-22       Impact factor: 43.330

4.  Ozonated autohemotherapy elevates PPAR-γ expression in CD4+ T cells and serum HDL-C levels, a potential immunomodulatory mechanism for treatment of psoriasis.

Authors:  Jinrong Zeng; Zhen Tang; Yuezhong Zhang; Xiaoliang Tong; Jianhua Dou; Lihua Gao; Shu Ding; Jianyun Lu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 5.  Immune regulation of metabolic homeostasis in health and disease.

Authors:  Jonathan R Brestoff; David Artis
Journal:  Cell       Date:  2015-03-26       Impact factor: 41.582

Review 6.  Adipose tissue inflammation in the pathogenesis of type 2 diabetes.

Authors:  Ayano Kohlgruber; Lydia Lynch
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

7.  Mouse tail models of secondary lymphedema: fibrosis gradually worsens and is irreversible.

Authors:  Chenxiao Zhou; Wanchun Su; Haotian Han; Na Li; Gang Ma; Lei Cui
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

8.  The Tpl2 Kinase Regulates the COX-2/Prostaglandin E2 Axis in Adipocytes in Inflammatory Conditions.

Authors:  Flavien Berthou; Franck Ceppo; Karine Dumas; Fabienne Massa; Bastien Vergoni; Susana Alemany; Mireille Cormont; Jean-François Tanti
Journal:  Mol Endocrinol       Date:  2015-05-28

9.  Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity.

Authors:  Carly B Garrison; Kristin J Lastwika; Yuzheng Zhang; Christopher I Li; Paul D Lampe
Journal:  J Proteome Res       Date:  2016-11-14       Impact factor: 4.466

Review 10.  Metabolism disrupting chemicals and metabolic disorders.

Authors:  Jerrold J Heindel; Bruce Blumberg; Mathew Cave; Ronit Machtinger; Alberto Mantovani; Michelle A Mendez; Angel Nadal; Paola Palanza; Giancarlo Panzica; Robert Sargis; Laura N Vandenberg; Frederick Vom Saal
Journal:  Reprod Toxicol       Date:  2016-10-17       Impact factor: 3.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.